Mortality reduction by antiadrenergic modulation of arrhythmogenic substrate: Significance of combining beta blockers and amiodarone

American Journal of Cardiology

Volumn 84, Issue 9 SUPPL. 1, 1999, Pages 76-82

  Ogunyankin, Kofo O ^a   Singh, Bramah N ^b  

^a Division of Cardiology   (United States)

^b Research Institute in Los Angeles   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; SOTALOL;

CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DRUG POTENTIATION; HEART ARRHYTHMIA; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; MORTALITY; PRIORITY JOURNAL; SURVIVAL;

EID: 0032730428     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00706-7     Document Type: Conference Paper

References (55)

1. Cohn J.N. Sympathetic nervous system activity and the heart. Am J Hypertens. 2:1989;353S-356S.
2. Julius S. Sympathetic hyperactivity and coronary artery risk in hypertension. Hypertension. 21:1993;886-891.
3. Leenen F.H. Cardiovascular consequences of sympathetic hyperactivity. Can J Cardiol. 15:(suppl A):1999;2A-7A.
4. Zipes D.P. An overview of arrhythmias and antiarrhythmic approaches. J Cardiovasc Electrophysiol. 10:1999;267-271.
5. Schwartz P.J., La Rovere M.T., Vanoli E. Autonomic nervous system and sudden cardiac death experimental basis and clinical observations for post-myocardial infarction risk stratification . Circulation. 85:(suppl):1992;77-87.
6. Meredith I.T., Broughton A., Jennings G.L., Esler M.D. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med. 325:1991;618-624.
7. Reiter M.J., Reiffel J.A. Importance of beta blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol. 82:1998;9I-19I.
8. Singh BN. Pharmacological actions of certain cardiac drugs and hormones: focus on antiarrhythmic mechanisms. D. Phil. Thesis, 1971; Hertford College & University of Oxford. England. Published also by Futura Publishing Co, Mt Kisco, NY 1991:1-98.
9. Singh B.N., Vaughan Williams E.M. A third class of antiarrhythmic action effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ1999 and AH 3474 . Br J Pharmacol. 39:1970;675-687.
10. Singh B.N., Vaughan Williams E. The effect of amiodarone, a new antianginal drug, on cardiac muscle. Br J Pharmacol. 39:1970;657-667.
11. Nattel S. Antiarrhythmic drug classifications a critical appraisal of their history, present status, and clinical relevance . Drugs. 41:1991;672-701.
12. Singh B.N., Hauswirth O. Comparative mechanisms of action of antiarrhythmic drugs. Am Heart J. 87:1974;367-377.
13. Schwartz P.J. The idopathic long QT interval syndrome progress and questions . Am Heart J. 109:1985;399-405.
14. Tan H.L., Hou C.J., Lauer M.R., Sung R.J. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Intern Med. 122:1995;701-714.
15. Steinbeck G., Andersen D., Bach P., Haberi R., Oeff M., Hoffman E., Von Leitner E.R. A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy to patients with symptomatic sustained tachyarrhythmias. N Engl J Med. 327:1992;987-993.
16. Wiesfeld A.C., Crijns H.J., Tuininga Y.S., Lie K.I. Beta adrenergic blockade in the treatment of sustained ventricular tachycardia or ventricular fibrillation. Pacing Clin Electrophysiol. 19:1996;1026-1035.
17. Hallstrom A.P., Cobb L.A., Yu B.H., Weaver W.D., Fahrenbruch C.E. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol. 68:1991;1025-1031.
18. Yusuf S., Peto R., Lewis J., Sleight P. Beta-blockade during myocardial infarction an overview of randomized trials . Prog Cardiovasc Dis. 27:1985;335-355.
19. Yusuf S., Wittes J., Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA. 260:1988;2088-2093.
20. Green K.G., Chamberlain D.A., Fulton R.M., Hamer N.A.J., Oliver M.F., Pentecost B.L., Lewis J.A., Tuson R. Multicentre international study supplementary report. Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade . BMJ. 2:1977;419-421.
21. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 304:1981;801-807.
22. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 247:1982;1707-1714.
23. Metoprolol in acute myocardial infarction (MIAMI) a randomised placebo-controlled international trial . Eur Heart J. 6:1985;199-226.
24. Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction ISIS-1. ISIS-1 (First International Study of Infarct Survival) . Lancet. 1:1988;921-923.
25. Kendall M.J., Lynch K.P., Hjalmarson A., Kjekshus J. Beta-blockers and sudden cardiac death. Ann Intern Med. 123:1995;358-367.
26. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol. 80:(suppl):1997;35J-39J.
27. Avanzini F., Zuanetti G., Latini R., Colombo F., Santoro E., Maggioni A.P., Franzosi M.G., Tognoni G. Use of beta-blocking agents in secondary prevention after myocardial infarction a case for evidence-based medicine? GISSI experience, 1984-1993. The Gruppo Italiano di Studio sulla Sopravvivenza nell'Infarto Miocardico (GISSI) Investigators . Eur Heart J. 18:1997;1447-1456.
28. Pfisterer M., Cox J.L., Granger C.B., Brener S.J., Naylor C.D., Califf R.M., van de Werf F., Stebbins A.L., Lee K.L., Topol E.J., Armstrong P.W. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries . J Am Coll Cardiol. 32:1998;634-640.
29. Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 339:1998;489-499.
30. Roberts R., Rogers W.J., Mueller H.S., Lambrew C.T., Diver D.J., Smith H.C., Willerson J.T., Knatterud G.L., Forman S., Passamani E., Zaret B.L., Wackers F.J.T., Braunwald E. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation. 83:1991;422-437.
31. Teerlink JR, Bassie BM. Beta-adrenergic blocker mortality trials in congestive heart failure. Am J Cardiol. 1999;94R-102R.
32. Packer M., Colucci W.S., Sackner-Bernstein J.D., Liang C.S., Goldscher D.A., Freeman I., Kukin M.L., Kinhal V., Udelson J.E., Klapholz M., Gottlieb S.S., Pearle D., Cody R.J., Gregory J.J., Kantrowitz N.E., LeJemtel T.H., Young S.T., Lukas M.A., Shusterman N.H. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The Precise Trial. Circulation. 94:1996;2793-2801.
33. Packer M., Bristow M.R., Cohn J.N. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
34. Effect of metoprolol CR/XL in chronic heart failure Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF) . Lancet. 353:1999;2001-2007.
35. The cardiac insufficiency bisoprolol study II (CIBIS II). Lancet. 353:1999;9-13.
36. Singh B.N. Current antiarrhythmic drugs an overview of mechanisms of action and potential clinical utility . J Cardiovasc Electrophysiol. 10:1999;283-301.
37. Marchlinski FE, Zado ES, Deely MP, Saligan J, Ashar M, Nayak H. Concomitant device and drug therapy: current trends, potential benefits, and adverse interactions. Am J Cardiol. 1999;69R-75R.
38. Farshi R., Kistner D., Sarma J.S., Longmate J.A., Singh B.N. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise a crossover open-label study of five drug regimens . J Am Coll Cardiol. 33:1999;304-310.
39. Lillie C., Singh B.N. Sinus node inhibitors. Singh B.N., Dzau V.J., Vanhoutte P.M., Woosley R.L. Cardiovascular Pharmacology and Therapeutics. 1994;203-216 Churchill Livingstone, New York.
40. Julian D.G., Prescott R.J., Jackson F.S., Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet. 1:1982;1142-1147.
41. Waldo A.L., Camm A.J., deRuyter H., Friedman P.L., MacNeil D.J., Pauls J.F., Pitt B., Pratt C.M., Schwartz P.J., Veltri E.P. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 348:1996;7-12.
42. Chadda K., Goldstein S., Byington R., Curb J.D. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 73:1986;503-513.
43. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol. 80:(suppl):1997;35J-39J.
44. Singh B.N. Arrhythmia control by prolonging repolarization the concept and its potential therapeutic impact . Eur Heart J. 14:1993;14-23.
45. Singh B.N. Antiarrhythmic actions of amiodarone a profile of a paradoxical agent . Am J Cardiol. 78:1996;41-53.
46. Sicouri S., Moro S., Litovsky S., Elizari M.V., Antzelevitch C. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol. 8:1997;1269-1279.
47. Charlier R. Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors. Br J Pharamcol. 39:1970;668-674.
48. Kadish A.H., Chen R.F., Smaltz S., Morday F. Magnitude and time course of beta-adrenergic antagonism during oral amiodarone therapy. J Am Coll Cardiol. 16:1990;1240-1245.
49. Julian D.G., Camm A.J., Frangin G., Janse M.J., Munoz A., Schwartz P.J., Simon P. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction EMIAT . Lancet. 349:1997;667-673.
50. Cairns J.A., Connolly S.J., Roberts R.J., Gent M. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations CAMIAT . Lancet. 394:1997;675-682.
51. The effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure meta-analysis of individual patient data on 6,500 patients from randomized trials . Lancet. 350:1997;1417-1424.
52. Tonet J., Frank R., Fontaine G., Grosgogeat Y. Efficacy and safety of low doses of beta-blocker agents combined with amiodarone in refractory ventricular tachycardia. PACE Pacing Clin Electrophysiol. 11:1988;1984-1989.
53. Boutitie F., Boissel J.P., Connolly S.J., Camm A.J., Cairns J.A., Julian D.G., Gent M., Janse M.J., Dorian P., Frangin G. Amiodarone Interaction with β-Blockers analysis of the merged EMIAT and CAMIAT databases . Circulation. 99:1999;2268-2275.
54. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 337:1997;1576-1583.
55. Singh BN. Antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias - the AVID trial: commentary and reflections. In: RJ Woosley and SN Singh, eds. 1999; in press.